ORIGINS next-generation biotechnology platform

At Galaxy Genomics, we are developing a next-generation biotechnology platform to accelerate and improve the analysis, design, and creation of new drugs, food, and substances.

The Origins biotechnology platform, currently in development, uses advanced mathematical and computational algorithms to deliver value to our users. It allows them to create proteins, peptides, and enzymes accurately, achieve significant reductions in cost and time, and develop superior and innovative products.

Proteins, peptides, and enzymes are the core building blocks of all biological structures. 

The business applications are endless, from the development of safer and more effective drugs, to next-generation antibiotics and vaccines, the creation of living medicines, and improvements in industrial processes and substances for the cosmetics sector.

Learn more about Galaxy Genomics Corp. and the Origins Biotechnology Platform:

Origins platform demo video

Corporate Presentation (Dropbox): https://lnkd.in/gxT5gdu3

Sign up for early access to the Origins platform: https://lnkd.in/gw_taRKC

Investor contact: Jose Ponce | Co-founder | Galaxy Genomics Corp. | jponce@galaxygenomics.com

#genomics #business #biotechnology #algorithms #development #food #design #cosmetics #pharmaceutical #pharmaindustry #pharmaceuticals #nutraceuticals #venturecapital #investor #privateequity #dnasequencing #dna #oilandgas #cannabisindustry #chemical #industrial #machinelearning #artificialintelligence